Neurocrine Biosciences Inc (NBIX) Stock Analysis

Neurocrine Biosciences Inc (NBIX) is a publicly traded company in the HEALTHCARE sector. It trades at $154.84, carries a market capitalization of $16.19B, a price-to-earnings ratio of 24.77. This page summarizes the public market data, fundamentals, and frequently asked questions for NBIX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Neurocrine Biosciences Inc currently has a Bullish sentiment score of 0.17.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. (NBIX), based in San Diego, California, is a leading biopharmaceutical company specializing in the development of innovative treatments for neurological, endocrine, and psychiatric disorders. The company boasts a robust pipeline, including advanced therapies targeting Parkinson's disease, epilepsy, and various other serious medical conditions, addressing critical unmet needs in patient care. Neurocrine's commitment to scientific excellence and strategic partnershi...

GNG Research Analysis

GNG Research scores Neurocrine Biosciences Inc (NBIX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NBIX.

Frequently Asked Questions

Does NBIX pay dividends?

Neurocrine Biosciences Inc (NBIX) does not currently pay a regular dividend.

What is NBIX's P/E ratio?

Neurocrine Biosciences Inc has a price-to-earnings (P/E) ratio of 24.77.

What is NBIX's market cap?

Neurocrine Biosciences Inc (NBIX) has a market capitalization of $16.19B with a current stock price of $154.84.